SurpassMD Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.3/10
Best for: budget-conscious GLP-1 shoppers wanting broad state coverage
SurpassMD stands out for its medical oversight and pharmacy verification.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Not disclosed
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
SurpassMD is an online GLP-1 weight loss platform operated by Life Vitality LLC that connects patients with independent licensed providers for compounded semaglutide and tirzepatide, dispensed by 503A pharmacies with cold-chain shipping. Its clinical intake and consent flow runs on OpenLoop's telehealth platform. Pricing starts as low as $124/month for semaglutide and $184/month for tirzepatide for eligible patients, cash-pay only, with HSA/FSA and Klarna-style financing accepted.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to SurpassMD
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Brightmeds
Best for: compounded or brand GLP-1 bundled with TRT and peptides for men
Editorial score · methodology
SurpassMD at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $124/mo (Homepage/FAQ: 'Semaglutide starts as low as $124/m ... for eligible patients. Actual pricing depends on medication, dose, and provider approval.')
- What's included
- Consult · Medication
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How we scored SurpassMD
Each dimension is scored algorithmically from SurpassMD’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
7.8/10At $124/mo, SurpassMD runs about 27% below the $169 median for GLP-1 providers.
Effectiveness25%
7.3/10SurpassMD offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
6.6/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
8.0/10Key details fully confirmed by our editors; no FDA warning letters on file; dispenses through an accredited compounding pharmacy (last checked 2026-08-06).
Accessibility10%
7.9/10SurpassMD treats patients in all 50 states. FSA/HSA cards are accepted.
Support10%
5.1/10SurpassMD provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this SurpassMD review
Last checked August 2026- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: high.
What to expect when you sign up with SurpassMD
We walked SurpassMD’s public signup flow in August 2026 to document the process — the steps, pricing transparency, and what’s required — before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Landing step: 'Start my free assessment' (no payment required)
- 2Enter height (feet/inches) and weight (lbs); app auto-calculates BMI
- 3Select a weight-loss goal (e.g., 'Lose 21-50 lbs for good')
- 4Select reasons for wanting to change (life expectancy, appearance, health risks, mental health)
- 5View a personalized 3-month weight-projection chart, explicitly disclaimed as an estimate based on other patients, not a guarantee
- 6Enter email and check a mandatory box agreeing to OpenLoop's Telehealth Consent, Terms of Use, and Notice of Privacy Practices
- Starting prices ($124/mo semaglutide, $184/mo tirzepatide) are published on the homepage FAQ, reachable before starting the quiz — but the quiz itself never displays a price during the portion we could reach.
- The funnel's required consent step names OpenLoop (openloophealth.com) as the party behind the Telehealth Consent, Terms of Use, and Notice of Privacy Practices you must accept — this is not disclosed anywhere on SurpassMD's own marketing pages or its own Terms of Use, which only refer to an unnamed 'independent professional medical corporation.'
- The marketing-email opt-in checkbox is unchecked by default and optional; the OpenLoop telehealth consent checkbox is mandatory to proceed.
- A reCAPTCHA challenge on the email-capture step blocked further automated progress, so the health-history questionnaire and an actual plan-selection/checkout screen could not be reached — the true per-dose price ladder and exact billing cadence (monthly vs. every-4-weeks) could not be independently confirmed beyond the Terms of Use's generic billing-cycle language.
- Per the separate Refund Policy page, billing begins as soon as the intake form is submitted — before the licensed provider reviews or approves treatment — though a full refund is promised if you are disqualified.
SurpassMD customer support
- Phone
- 1-502-515-4576
- care@surpassmd.com
- Hours
- Monday-Friday, 9 AM-6 PM PT
GLP-1 medications SurpassMD offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Prices re-verified
Homepage/FAQ: 'Semaglutide starts as low as $124/m ... for eligible patients. Actual pricing depends on medication, dose, and provider approval.'
Homepage/FAQ: 'tirzepatide starts as low as $184/m ... for eligible patients. Actual pricing depends on medication, dose, and provider approval.'
Ready to get started?
Plans and promotions change often — check SurpassMD's current pricing and active discounts before you decide.
What we like
- Transparent starting prices published: $124/mo semaglutide, $184/mo tirzepatide
- Compounded through 503A pharmacies with cold-chain shipping
- Broad coverage: licensed to operate in all 50 states plus DC
- HSA/FSA and Klarna-style buy-now-pay-later accepted
- Free assessment with no payment required to see if you qualify
- Full refund if disqualified by the medical provider
Watch-outs
- Specific compounding pharmacy partner is not named on the site
- LegitScript Certified badge shown, but no verifiable LegitScript record found
- Cancellation & Refund Policy page conflicts with the Terms of Use on refund eligibility
- Billing begins at intake submission, before provider approval
- Exact per-dose pricing beyond the 'starting at' figures is not published
- Refund policy requires 72 hours' notice before your next billing date to cancel
Is SurpassMD worth it? Our verdict
SurpassMD positions itself around one thing: budget-conscious GLP-1 shoppers wanting broad state coverage. It runs $124/month — toward the affordable end of the market. It treats patients in all 50 states, so access isn't a barrier.
On top of the prescription itself, SurpassMD points to 503A Compounding, Cold-Chain Shipping, and HSA/FSA Accepted.
How much SurpassMD actually costs
- Compounded semaglutide — $124/month
- Compounded tirzepatide — $184/month
That puts SurpassMD below the roughly $169 median ongoing price across the GLP-1 providers we track — a real cost advantage.
For a direct comparison, Oak runs semaglutide and tirzepatide from $119/month — worth pricing against SurpassMD before you commit.
Medications: what SurpassMD prescribes
SurpassMD prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. The medication is compounded at a licensed pharmacy rather than sold as a brand pen, which is what keeps the price down. The trade-off is the one every compounded provider shares: compounded drugs aren't FDA-approved as finished products.
Who SurpassMD is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
- live anywhere in the US and want guaranteed access.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
SurpassMD treats patients in all 50 states, and dispenses through an accredited compounding pharmacy. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
SurpassMD earns its place on the shortlist mainly on price: at $124/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
The Bottom Line
SurpassMD stands out for its medical oversight and pharmacy verification.
Ready to start with SurpassMD?
Starting at $124/month. See current pricing and start your free consultation.
SurpassMD might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider GobyMeds.
- If the lowest possible monthly price is your top priority, consider Sesame Care (from $59/mo).
- If you want built-in coaching and behavior-change support, consider Oak.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this SurpassMD review:
Sources & methodology — as of August 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See SurpassMD's current pricing
Plans start at $124/month. Start your free consultation to check eligibility and today's price.